{
    "ticker": "MMD",
    "name": "MannKind Corporation",
    "description": "MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for patients with diabetes and other endocrine diseases. Founded in 1991 and headquartered in Danbury, Connecticut, MannKind is best known for its proprietary inhaled insulin product, Afrezza, which offers a unique delivery system for managing blood sugar levels in diabetes patients. Afrezza is administered via a small, portable inhaler, providing a non-injection alternative that allows for greater flexibility in insulin management. Beyond Afrezza, MannKind is engaged in research and development of other therapeutic products, leveraging its Technosphere technology platform to create inhalable forms of a variety of medications. The company is committed to improving the quality of life for patients through innovative solutions and has established partnerships to expand its product offerings. With a dedicated team and a strong pipeline, MannKind aims to address unmet medical needs in the diabetes space and beyond. The company continues to focus on building its market presence and exploring new applications for its technology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Danbury, Connecticut, USA",
    "founded": "1991",
    "website": "https://www.mannkindcorp.com",
    "ceo": "Michael Castagna",
    "social_media": {
        "twitter": "https://twitter.com/MannKindCorp",
        "linkedin": "https://www.linkedin.com/company/mannkind-corporation/"
    },
    "investor_relations": "https://investors.mannkindcorp.com",
    "key_executives": [
        {
            "name": "Michael Castagna",
            "position": "CEO"
        },
        {
            "name": "Cheryl McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Inhaled Insulin",
            "products": [
                "Afrezza"
            ]
        },
        {
            "category": "Technosphere Technology",
            "products": [
                "Inhalable Therapeutics"
            ]
        }
    ],
    "seo": {
        "meta_title": "MannKind Corporation | Innovative Diabetes Solutions",
        "meta_description": "Explore MannKind Corporation, a biopharmaceutical leader in inhaled insulin and innovative therapies for diabetes management. Learn about Afrezza and our commitment to patient care.",
        "keywords": [
            "MannKind",
            "Afrezza",
            "Inhaled Insulin",
            "Diabetes Management",
            "Biopharmaceuticals",
            "Technosphere Technology"
        ]
    },
    "faq": [
        {
            "question": "What is MannKind known for?",
            "answer": "MannKind is known for its inhaled insulin product, Afrezza, and its innovative Technosphere technology."
        },
        {
            "question": "Who is the CEO of MannKind?",
            "answer": "Michael Castagna is the CEO of MannKind Corporation."
        },
        {
            "question": "Where is MannKind headquartered?",
            "answer": "MannKind is headquartered in Danbury, Connecticut, USA."
        },
        {
            "question": "What are MannKind's main products?",
            "answer": "MannKind's main product is Afrezza, an inhaled insulin, along with its Technosphere technology for inhalable therapeutics."
        },
        {
            "question": "When was MannKind founded?",
            "answer": "MannKind was founded in 1991."
        }
    ],
    "competitors": [
        "VRTX",
        "BMY",
        "PFE",
        "SNY"
    ],
    "related_stocks": [
        "JNJ",
        "AMGN",
        "GILD",
        "ABBV"
    ]
}